Literature DB >> 17351724

Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.

Helmut Neumann, Antal Csepregi, Michael Sailer, Peter Malfertheiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17351724     DOI： 10.1007/s00415-006-0441-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report.

Authors:  C Heesen; J Gbadamosi; B G Schoser; D Pöhlau
Journal:  Eur J Neurol       Date:  2001-03       Impact factor: 6.089

2.  Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.

Authors:  A Frese; F Bethke; P Lüdemann; F Stögbauer
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

3.  Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy.

Authors:  Mathew Pulicken; Ayman Koteish; Karen DeBusk; Peter A Calabresi
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

4.  Autoimmune hepatitis and multiple sclerosis: a coincidental association?

Authors:  J de Seze; V Canva-Delcambre; I Fajardy; S Delalande; T Stojkovic; E Godet; P Vermersch
Journal:  Mult Scler       Date:  2005-12       Impact factor: 6.312

5.  Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.

Authors:  L Speciale; M Saresella; D Caputo; S Ruzzante; R Mancuso; M G Calvo; F R Guerini; P Ferrante
Journal:  J Neurovirol       Date:  2000-05       Impact factor: 2.643

Review 6.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.

Authors:  R Aharoni; D Teitelbaum; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

8.  Multiple sclerosis and other immunologic diseases.

Authors:  S Seyfert; P Klapps; C Meisel; T Fischer; U Junghan
Journal:  Acta Neurol Scand       Date:  1990-01       Impact factor: 3.209

9.  Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

Authors:  A Miller; S Shapiro; R Gershtein; A Kinarty; H Rawashdeh; S Honigman; N Lahat
Journal:  J Neuroimmunol       Date:  1998-12-01       Impact factor: 3.478
  9 in total
  5 in total

1.  Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.

Authors:  Naila Makhani; Bo-yee Ngan; Binita M Kamath; E Ann Yeh
Journal:  Neurology       Date:  2013-07-24       Impact factor: 9.910

2.  Acute hepatitis induced by glatiramer acetate.

Authors:  Pierre Deltenre; Marie-Odile Peny; André Dufour; Mohamed El Nady; Jean Henrion
Journal:  BMJ Case Rep       Date:  2009-02-27

3.  Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report.

Authors:  Attila Onmez; Ahmet Tarik Eminler; Hasan Ergenç; Meltem Baykara; Ihsan Uslan; Ali Tamer
Journal:  J Investig Med High Impact Case Rep       Date:  2013-12-17

Review 4.  Liver injury and glatiramer acetate, an uncommon association: case report and literature review.

Authors:  Javier Almeida; Nuria Solà-Valls; Elisa Pose; Yolanda Blanco; María Sepúlveda; Sara Llufriu; Pere Gines; Albert Saiz
Journal:  Ther Adv Neurol Disord       Date:  2017-07-26       Impact factor: 6.570

Review 5.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.